Brown Advisory Inc. Acquires 14,049 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Brown Advisory Inc. raised its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 2.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 570,258 shares of the company's stock after buying an additional 14,049 shares during the period. Brown Advisory Inc. owned approximately 0.44% of Vaxcyte worth $21,533,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its holdings in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after acquiring an additional 260 shares during the last quarter. Assetmark Inc. boosted its position in shares of Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after purchasing an additional 775 shares during the period. Proficio Capital Partners LLC purchased a new position in Vaxcyte in the 4th quarter worth about $2,915,000. Raymond James Financial Inc. acquired a new stake in Vaxcyte during the 4th quarter worth about $21,669,000. Finally, PNC Financial Services Group Inc. lifted its stake in Vaxcyte by 18.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,076 shares of the company's stock valued at $743,000 after buying an additional 1,397 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Upgrades and Downgrades

PCVX has been the topic of several analyst reports. Bank of America dropped their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. The Goldman Sachs Group decreased their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Cantor Fitzgerald began coverage on Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating on the stock. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Down 0.9%

Shares of Vaxcyte stock traded down $0.31 on Friday, hitting $35.93. 1,947,376 shares of the company traded hands, compared to its average volume of 1,489,935. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The company has a market cap of $4.63 billion, a PE ratio of -9.01 and a beta of 1.19. The company has a 50-day moving average price of $33.31 and a 200 day moving average price of $55.46.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the previous year, the business earned ($0.85) earnings per share. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.